IN8bio
New York, New York, United States · Biotechnology, Therapeutics
IN8bio is a clinical-stage biopharmaceutical company advancing gamma-delta T cell therapies for the treatment of cancer, leveraging its proprietary DeltEx platform to develop ex vivo–expanded, activated, and genetically modified cell therapies using allogeneic and autologous approaches. As the most clinically advanced company in this field, IN8bio combines deep expertise in gamma-delta T cell biol
Key facts
- Headquarters
- New York, New York, United States
- Employees
- 26
- Industries
- Biotechnology, Therapeutics
- Status
- Public (INAB)
- Website
- in8bio.com
- Company page
Recent activity at IN8bio
- : IN8bio Appoints Oxana Polyakova, Ph.D. as Senior Vice President of R&D
- : IN8bio
- : SEC 8-K (1.01): On December 18, 2025, IN8bio, Inc. entered into a Securities Purchase Agreement with certain investors to sell up to 5,127,029 shares of its common stock, par value $0.0001 per share. The agreement includes provisions for pre-funded warrants that allow the investors to purchase additional shares of common stock. The initial closing of this private placement is expected to take place on or about December 22, 2025, subject to customary closing conditions. This transaction potentially boosts the company's capital, enabling further investment into its business operations.
- : IN8bio
- : IN8bio
- : In8Bio Announces Pricing Of Financing Totaling Up To $46.9 Million In Private Placement
- : IN8BIO, INC.
- : Incysus Therapeutics, Inc.
- : Incysus Therapeutics, Inc.
IN8bio funding history
| Date | Round | Amount |
|---|---|---|
| Dec 2025 | Venture | $20.1M |
| Oct 2024 | Venture | $12.4M |
| Dec 2023 | Venture | $35.0M |
| Dec 2023 | Post-IPO Equity | Undisclosed |
| Sep 2020 | Venture | $35.0M |
Leadership
- William Ho, Executive Officer, Director
- Thomas Cirrito, Director
- Travis Whitfill, Director
- Peter Brandt, Director
- Travis Whitfill, Director
- Thomas Cirrito, Director
- William Ho, Executive Officer, Director
- Travis Whitfill, Director
- Thomas Cirrito, Director
- William Ho, Executive Officer, Director
- Oxana Polyakova, Ph.D., Senior Vice President
- Lawrence Lamb, Executive Vice President
Verified email and direct lines for IN8bio’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
IN8bio in the news
- IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire (Oct 06, 2026)
- IN8bio to Present at Sidoti Small-Cap Virtual Conference - GlobeNewswire (Sep 22, 2026)
- IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire (Sep 10, 2026)
- IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences - Yahoo Finance (May 06, 2026)
- IN8bio halts phase 2 glioblastoma trial, lays off half of workforce to focus on leukemia cell therapy - Fierce Biotech (Sep 05, 2024)
- IN8bio’s Gamma-Delta T-cell Therapy INB-100 Helps Maintain Complete Remissions After HSCT in Patients With Hematologic Malignancies - CGTLive® (Jun 13, 2024)
- IN8bio to Participate in Immuno-Oncology 360° Conference 2025, Highlighting Advances in Gamma-Delta T Cell Therapies - Quiver Quantitative (Mar 18, 2025)
- Clinical Development of Gamma-Delta T-Cell Therapy INB-400 Paused in Glioblastoma - OncLive (Sep 11, 2024)
Companies similar to IN8bio
- GenSight Biologics · Biotechnology, Therapeutics
- Valink Therapeutics · Biotechnology, Therapeutics
- Neogap Therapeutics · Biotechnology, Therapeutics
- Mosaic Therapeutics · Biotechnology, Therapeutics
- Nuvig Therapeutics · Biotechnology, Therapeutics
About IN8bio: questions and answers
What does IN8bio do?
IN8bio is a clinical-stage biopharmaceutical company advancing gamma-delta T cell therapies for the treatment of cancer, leveraging its proprietary DeltEx platform to develop ex vivo–expanded, activated, and genetically modified cell therapies using allogeneic and autologous approaches. As the most clinically advanced company in this field, IN8bio combines deep expertise in gamma-delta T cell biol
Where is IN8bio headquartered?
IN8bio is headquartered in New York, New York, United States.
How many employees does IN8bio have?
IN8bio has about 26 employees.
Has IN8bio raised funding?
Yes. Fundz has recorded 5 funding events for IN8bio. The most recent, $20.1M, was in Dec 2025.
Who leads IN8bio?
Oxana Polyakova, Ph.D. is a Senior Vice President at IN8bio.
What is the latest news on IN8bio?
On Sep 09, 2026, IN8bio Appoints Oxana Polyakova, Ph.D. as Senior Vice President of R&D
Is IN8bio a public company?
Yes. IN8bio is publicly traded under the ticker INAB.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy